Related Experiment Video
Updated: Jan 11, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Persistent systemic interleukin-6 elevation after community-acquired pneumonia is associated with one-year mortality
Mónica Piqueras1,2,3, Paula González-Jiménez4,5,6, Ana Latorre1
1Respiratory Infections. Health Research Institute La Fe (IISLAFE), Valencia, Spain.
Persistent inflammation markers like interleukin-6 (IL-6) and C-reactive protein (CRP) 30 days post-community-acquired pneumonia (CAP) predict increased long-term mortality risk.
Area of Science:
- Infectious Diseases
- Immunology
- Cardiovascular Medicine
Background:
- Community-acquired pneumonia (CAP) is a leading cause of death globally.
- Long-term complications and increased mortality following CAP are increasingly recognized.
- Systemic inflammation may play a role in post-CAP outcomes.
Purpose of the Study:
- To assess systemic inflammation at 30 days post-CAP using interleukin-6 (IL-6) and C-reactive protein (CRP).
- To determine the association between these biomarkers and one-year mortality after CAP.
Main Methods:
- Post-hoc analysis of a prospective observational study.
- Included 268 patients discharged alive after CAP and 15 healthy controls.
- Measured IL-6 and CRP levels at 30 days post-discharge; one-year mortality tracked via records and interviews.
Main Results:
- Patients with CAP showed higher IL-6 and CRP levels at 30 days compared to controls.
- Elevated IL-6 and CRP levels were significantly associated with increased one-year mortality.
- These findings suggest ongoing low-grade systemic inflammation post-CAP.
Conclusions:
- Biomarkers of systemic inflammation (IL-6, CRP) at 30 days post-CAP are linked to long-term mortality.
- Persistent inflammation may indicate incomplete recovery or impaired homeostasis after pneumonia.
- These readily available markers could aid in identifying high-risk patients for closer monitoring.
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

